Scarica l'app Stockscreener
8.00
1.72%
-0.14
Precedente Chiudi:
$8.14
Aprire:
$8.22
Volume 24 ore:
2.23M
Relative Volume:
2.80
Capitalizzazione di mercato:
$412.77M
Reddito:
$676.80M
Utile/perdita netta:
$-8.60M
Rapporto P/E:
-28.28
EPS:
-0.2829
Flusso di cassa netto:
$135.40M
1 W Prestazione:
-4.65%
1M Prestazione:
-1.60%
6M Prestazione:
-34.96%
1 anno Prestazione:
+26.78%
Intervallo 1D:
$7.895
$8.32
Intervallo di 1 settimana:
$7.58
$8.49
Portata 52W:
$5.615
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.00 | 412.77M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Why Emergent’s Narcan nasal spray is becoming a quiet everyday life saver - AD HOC NEWS
Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Emergent BioSolutions Inc (EBS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Emergent BioSolutions Inc (EBS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Emergent BioSolutions Inc (EBS) Institutional Confidence - TradingKey
Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Emergent BioSolutions Inc (EBS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Emergent BioSolutions Inc (EBS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Emergent BioSolutions Stock (US29089Q1058): Earnings Picture And Balance Sheet Under The Microscope - AD HOC NEWS
Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
[Form 4] Emergent BioSolutions Inc. Insider Trading Activity - Stock Titan
Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes - Stock Titan
Emergent BioSolutions (EBS) EVP uses 2,018 shares to cover RSU taxes - Stock Titan
Emergent BioSolutions (EBS) SVP reports 1,741-share tax withholding on RSU vesting - Stock Titan
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS) - Seeking Alpha
U.S. – Johnson & Johnson in charge of Baltimore vaccine facility - Digital Journal
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose - The Manila Times
Emergent (EBS) Q1 2026 Earnings Transcript - AOL.com
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Emergent BioSolutions (EBS) Consolidates Near Key Support After Flat SessionJurik MA - thelegaladvocate.com
Emergent BioSolutions (EBS) Secures $64.5M Contract Modification - GuruFocus
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)(Equine)] to Support U.S. Biodefense Strategy - The Manila Times
Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy - marketscreener.com
Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy - TradingView
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin ... - Caledonian Record
U.S. health agency awards $64.5M botulism antitoxin deal to Emergent - Stock Titan
EBS Technical Analysis | Trend, Signals & Chart Patterns | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
EBS Stock Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks - Stock Titan
Emergent Biosolutions donates thousands of NARCAN Nasal Spray units across the U.S. since 2021 - Traders Union
Emergent BioSolutions (EBS) Secures ACAM2000 Approval in Saudi A - GuruFocus
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - marketscreener.com
Saudi Arabia approves smallpox and mpox vaccine for people at high risk - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Stock Quote - The Chronicle-Journal
Global governments turn to Emergent Biosolutions for crisis health preparedness - Traders Union
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Common Stock (NY: EBS - FinancialContent
SABS: SAB-142 progresses in phase II-B with robust funding and regulatory clarity, targeting type 1 diabetes - TradingView
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance - MSN
Emergent BioSolutions Inc. (EBS): Investor Outlook with a Promising 31.43% Potential Upside - DirectorsTalk Interviews
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Harsanyi Zsolt - Moomoo
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.23%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):